Spherix Incorporated was launched in 1967 as a scientific research company. The company now leverages its scientific and technical expertise and experience through its two subsidiaries—Biospherics Incorporated and Spherix Consulting, Inc. Biospherics recently completed a global Phase 3 clinical trial investigating the use of D-Tagatose, an stereoisomer of fructose already marketed as a sugar substitute, as a treatment for glycemic control in patients with Type 2 diabetes. Preliminary studies suggest other indications include treatment of hypertriglyceridemia, dyslipidemias, the metabolic syndrome and atherosclerosis. The newest compound, SPX-106, is formulated with D-tagatose to make SPX-106T, which is being tested for use in reducing cholesterol, triglycerides and atherosclerosis.  Spherix Consulting provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides.

As its primary goals, Spherix is seeking to successfully commercialize SPX-106T worldwide, D-Tagatose in the U.S. and other markets, to advance its pre-clinical pipeline, and to promote its consulting practice as the premier product regulatory approval and scientific advisory service.

Spherix common stock trades on the NASDAQ under the symbol SPEX.

To be added to the current press release and/or fax distribution list email: subscriptions@spherix.com

To request information, please email: info@spherix.com

Or contact:

Investor Relations: 301.897.2564
Business Development: 301.897.2540

President: Robert A. Lodder, Ph.D.,   Lodder @ spherix.com

1-866-SPHERIX